<SEC-DOCUMENT>0000914475-24-000116.txt : 20240501
<SEC-HEADER>0000914475-24-000116.hdr.sgml : 20240501
<ACCEPTANCE-DATETIME>20240501070157
ACCESSION NUMBER:		0000914475-24-000116
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240501
DATE AS OF CHANGE:		20240501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		24900019

	BUSINESS ADDRESS:	
		STREET 1:		6027 EDGEWOOD BEND COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20240501.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cbb2df82-0ce2-472f-ba1e-879b30ce0587,g:ef90090a-678f-461a-91d5-1b279e91fac3,d:3fadea08f88c43efb6fceee6940a3150-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20240501</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20240501.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3fadea08f88c43efb6fceee6940a3150_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;1, 2024</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><img src="nbix-20240501_g1.jpg" alt="nbix.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(State or other jurisdiction<br/>of incorporation)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(Commission<br/>File Number)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.574%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0525145</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(IRS Employer<br/>Identification No.)</span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92130</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.467%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NBIX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3fadea08f88c43efb6fceee6940a3150_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;1, 2024, Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March&#160;31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.418%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q1-2024xearningsrelease.htm">Press Release dated May 1, 2024</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3fadea08f88c43efb6fceee6940a3150_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May&#160;1, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principle Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q1-2024xearningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4d257124615f4e5380332d20e71db0a4_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Neurocrine Biosciences Reports First Quarter 2024 Financial Results </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depressive Disorder</font></div><div style="margin-bottom:6pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SAN DIEGO, May 1, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today announced its financial results for the first quarter ended March&#160;31, 2024 and provided an update on its 2024 financial guidance.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Significant unmet need still exists for the many patients living with tardive dyskinesia as exemplified with INGREZZA&#8217;s first quarter year-over-year growth of 23%,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;With the recent New Drug Application submissions for crinecerfont, positive Phase 2 results for a potential first-in-class medication in NBI-&#8217;845 for major depressive disorder, and the deepest pipeline in our company&#8217;s history, Neurocrine Biosciences is well positioned to become a leader in neuroscience.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Highlights</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions, except per share data)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net Product Sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">509.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">515.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">420.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Research and Development (R&#38;D)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">159.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">142.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Selling, General and Administrative (SG&#38;A)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">243.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">215.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">216.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Net Income (Loss)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP Earnings (Loss) Per Share &#8211; Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP Net Income (Loss)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">124.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(49.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP Earnings (Loss) Per Share &#8211; Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total Cash, Cash Equivalents and Marketable Securities</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,911.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,719.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">INGREZZA Net Product Sales Highlights</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">INGREZZA first quarter 2024 net product sales were $506 million and grew 23% compared to the first quarter 2023</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">Year-over-year growth driven by strong underlying patient demand and improvement in gross-to-net dynamics</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Other Key Financial Highlights</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">Differences in first quarter 2024 GAAP and non-GAAP operating expenses compared with first quarter 2023 were driven by&#58;</font></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.54pt">Increased R&#38;D expense in support of an expanded and advancing clinical portfolio including preclinical investments in muscarinic compounds, gene therapy programs and second generation VMAT2 inhibitors</font></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.54pt">Flat SG&#38;A expense includes continued investment in INGREZZA and incremental investment in crinecerfont-related headcount and pre-launch activities</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">First quarter 2024 GAAP net income and earnings per share were $43 million and $0.42, respectively, compared with GAAP net loss and loss per share of $77 million and $0.79, respectively, for first quarter 2023</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">First quarter 2024 non-GAAP net income and earnings per share were $125 million and $1.20, respectively, compared with non-GAAP net loss and loss per share of $50 million and $0.51, respectively, for first quarter 2023</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">Differences in first quarter 2024 GAAP and non-GAAP net income compared with first quarter 2023 driven by&#58;</font></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.54pt">Higher INGREZZA net sales and improved operating margin</font></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.54pt">First quarter 2024 includes $89 million charge associated with convertible senior notes election to settle outstanding principal and conversion premium in cash (non-GAAP adjustment)</font></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.54pt">First quarter 2023 includes Acquired In-Process R&#38;D (IPR&#38;D) expense of $144 million associated with expansion of strategic partnership with Voyager Therapeutics, Inc. (Voyager)</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">At March&#160;31, 2024, the Company had cash, cash equivalents and marketable securities totaling approximately $1.9&#160;billion</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A reconciliation of GAAP to non-GAAP financial results can be found in Table 3 and Table 4 at the end of this news release.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Developments</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">In January, the Company elected to settle the convertible senior notes due May 2024 in cash.</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">In April, the Company reported positive Phase 2 data for its completed Phase 2 study of NBI-1065845 in adult subjects with major depressive disorder. The study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery &#197;sberg Depression Rating Scale (MADRS) total score at both Day 28 (primary endpoint) and Day 56 (key secondary endpoint).</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">In April, the Company submitted two New Drug Applications to the FDA for crinecerfont as a treatment for adult and pediatric patients with classic congenital adrenal hyperplasia.</font></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.6pt">In April, the Company received approval from the U.S. Food and Drug Administration for INGREZZA SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA (valbenazine) capsules.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Reaffirmed 2024 Net Sales Guidance and Updated Expense Guidance</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INGREZZA Net Product Sales </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,100&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,200&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP R&#38;D Expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">665&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">695&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D Expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">630&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP and Non-GAAP IPR&#38;D </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP SG&#38;A Expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">920&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">940&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A Expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3, 5</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">810&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">830&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington&#8217;s disease.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">GAAP R&#38;D guidance includes approximately $34 million expense for development milestones in connection with our collaborations (Nxera, Voyager and Takeda) achieved in first quarter 2024 or achievement is deemed probable in second quarter 2024. These milestone expenses are associated with our advancing pre-clinical and clinical pipeline.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">Non-GAAP guidance adjusted primarily to exclude estimated non-cash stock-based compensation expense of $65 million in R&#38;D and $110 million in SG&#38;A.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">Acquired in-process R&#38;D (IPR&#38;D) is included in guidance once significant collaboration and licensing arrangements have been completed.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">SG&#38;A guidance range reflects expense for ongoing commercial initiatives supporting INGREZZA growth including the expanded indication to treat chorea associated with Huntington&#8217;s disease and pre-launch commercial activities for crinecerfont.</font></div><div style="margin-bottom:3pt;text-indent:4.5pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;padding-left:8.6pt;text-decoration:underline">2024 Expected Pipeline Milestones and Key Activities</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Expected Milestones &#47; Key Activities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Selective VMAT2 Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sprinkle Formulation for Tardive Dyskinesia &#47; Chorea in Huntington&#8217;s Disease</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Approved by FDA on April 30, 2024</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Crinecerfont</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">CRF1 Receptor Antagonist</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia <br>(Pediatric and Adult)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Submitted New Drug Applications to the FDA</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1065845</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(AMPA Potentiator)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inadequate Response in Major Depressive Disorder</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reported Positive Top-Line Phase 2 Data&#59; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Engaging with FDA on Path Forward </font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Efmody</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Hydrocortisone Modified Release Hard Capsules)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adrenal Insufficiency</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reported Positive Top-Line Phase 2 Data</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Efmody</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Hydrocortisone Modified Release Hard Capsules)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reported Positive Top-Line Phase 2 Data</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1117568</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(M4 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schizophrenia</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Phase 2 Data in Q3&#8217;24</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Luvadaxistat</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(DAAO Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cognitive Impairment Associated with Schizophrenia</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Phase 2 Data in Q3&#8217;24</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1070770</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(NMDA NR2B NAM)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Major Depressive Disorder</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiated Phase 2 Study</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1065890</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Selective VMAT2 Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CNS Indications</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiated Phase 1 Study</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1117569</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(M4-Prefering Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CNS Indications</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiated Phase 1 Study</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1117570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(M1&#47;M4 Dual Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CNS Indications</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiated Phase 1 Study</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1117567</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(M1 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CNS Indications</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiating Phase 1 Study</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1076986</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(M4 Antagonist)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Movement Disorders</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiating Phase 1 Study</font></div></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key&#58; VMAT2 &#61; Vesicular Monoamine Transporter 2&#59; CFR1 &#61; Corticotropin-Releasing Factor Type 1&#59; AMPA &#61; alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid&#59; M4 &#61; M4 Muscarinic Receptor&#59; DAAO &#61; d-amino acid oxidase&#59; NMDA NR2B NAM &#61; n-methyl-d-aspartate Receptor Subtype 2B Negative Allosteric Modulator&#59; M1 &#61; M1 Muscarinic Receptor</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurocrine Biosciences Partners&#58; * Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia&#59;      ** Partnered with Takeda Pharmaceutical Company Limited&#59; &#8224; In-Licensed from Nxera Pharma UK Limited (formerly Sosei Heptares)</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast Today at 8&#58;00 AM Eastern Time</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences will hold a live conference call and webcast today at 8&#58;00 a.m. Eastern Time (5&#58;00 a.m. Pacific Time). Participants can access the live conference call by dialing 800-343-4136 (US) or 203-518-9814 (International) using the conference ID&#58; NBIX. The webcast and accompanying slides can also be accessed at approximately 8&#58;00 a.m. Eastern Time on Neurocrine Biosciences&#8217; website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">About Neurocrine Biosciences</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington&#8217;s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">in collaboration with AbbVie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NEUROCRINE BIOSCIENCES, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following non-GAAP financial measures&#58; non-GAAP R&#38;D expense, non-GAAP SG&#38;A expense, and non-GAAP net income and net income per share. When preparing the non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these non-GAAP financial measures exclude&#58; non-cash stock-based compensation expense, loss on extinguishment of convertible senior notes, charges associated with convertible senior notes, non-cash interest expense related to convertible debt, non-cash amortization expense related to acquired intangible assets, acquisition and integration costs, changes in fair value of equity security investments, changes in foreign currency exchange rates and certain adjustments to income tax expense. These non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these non-GAAP financial measures help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&#38;D and SG&#38;A expenses on both a GAAP and a non-GAAP basis. A reconciliation of these GAAP financial results to non-GAAP financial results is included in the attached financial information.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to&#58; the benefits to be derived from our products and product candidates&#59; the value our products and&#47;or our product candidates may bring to patients&#59; the continued success of INGREZZA&#59; our financial and operating performance, including our future revenues, expenses, or profits&#59; our collaborative partnerships&#59; expected future clinical and regulatory milestones&#59; and the timing of the initiation and&#47;or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58; our future financial and operating performance&#59; risks and uncertainties associated with the commercialization of INGREZZA&#59; risks related to the development of our product candidates&#59; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks associated with government and third-party regulatory and&#47;or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and&#47;or reimbursement for our products&#59; risks associated with competition from other therapies or products, including potential generic entrants for our products&#59; and other risks described in our periodic reports filed with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Contact&#58; Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tony Jewell (Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7578<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;neurocrine.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Todd Tushla (Investors)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;neurocrine.com</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:76.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.2)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity security investments</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges associated with convertible senior notes</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income and other, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.8)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before benefit from income taxes</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes </font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share, basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share, diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity security investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,472.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,251.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, at carrying value ($170.4 million face value)</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes embedded derivative liability</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,472.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,251.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net income (loss)</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense - R&#38;D</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense - SG&#38;A</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges associated with convertible senior notes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest related to convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash amortization related to acquired intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of equity security investments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect related to reconciling items </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.5)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Reflects charges associated with election to cash settle principal and conversion premium of convertible senior notes and the requirement to bifurcate the embedded conversion option and accrete to other expense.</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Reflects periodic fluctuations in the fair values of the Company&#8217;s equity security investments.</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Estimated income tax effect of non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance and adjustments to exclude tax benefits or expenses associated with charges associated with convertible senior notes and  non-cash stock-based compensation.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP EXPENSES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:74.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP cost of revenues</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash amortization related to acquired intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP cost of revenues</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP SG&#38;A</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP other (expense) income, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.8)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges associated with convertible senior notes</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest related to convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of equity security investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP other income, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20240501.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cbb2df82-0ce2-472f-ba1e-879b30ce0587,g:ef90090a-678f-461a-91d5-1b279e91fac3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20240501" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20240501">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20240501_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20240501_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20240501_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cbb2df82-0ce2-472f-ba1e-879b30ce0587,g:ef90090a-678f-461a-91d5-1b279e91fac3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_bca8219e-114a-414d-be7a-d0caecce2d1d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5e391c3d-1638-4464-9c9e-4bc3c345b041_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1b66a793-80e0-4c07-8ac6-c9dead1384af_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_611ee407-92b7-41eb-b36b-52ae83cdcdbe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_100a952b-784e-411d-bd90-1836d5b065d3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_548b1d97-b4d4-42d1-a2a7-7ae6c94638e9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2186efd9-441b-4768-920b-0f8291cfdd79_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1f618bfd-c27b-4789-bf29-6618d9689a41_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_08ea344f-5425-4eeb-8b3d-1e68c6576db9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6c2acbd8-0a31-49c6-ad6d-b39db4a80417_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_23a69b36-9582-48af-84e7-5f6ecbd8c6a9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_622b4c9e-644b-49a5-b9ed-1d8abfc3cc6a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_121398bd-f71d-4493-b685-4529cbe4cc98_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6cae0d8a-3c59-4bf0-9c64-d9fcb52b0c34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e7295987-4452-4af4-9c53-fce47a937927_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5254276a-12c2-421a-8a40-deeec6e7e937_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_20b3f02b-d86d-4214-8f4b-8a917bea5dec_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_eedf5418-4525-4199-8566-98518c3a3721_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0bfea14d-ee75-48e8-a20c-389cba937c62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_83764097-e367-4eb0-89a4-c5a12d1b241a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_35150869-41ab-49da-8486-edc1ae2dc365_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_def7a0b3-8ec0-48a6-b7bb-2442902350b7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20240501_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cbb2df82-0ce2-472f-ba1e-879b30ce0587,g:ef90090a-678f-461a-91d5-1b279e91fac3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20240501.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8a6af8ad-e112-4263-9a9e-62fdb688378a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_DocumentType_8a6af8ad-e112-4263-9a9e-62fdb688378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e4e455a4-e0a7-4f18-b5a0-ba4a6c40a2d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_DocumentPeriodEndDate_e4e455a4-e0a7-4f18-b5a0-ba4a6c40a2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_32c44586-924f-409c-ad8a-ff459f83bdb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityRegistrantName_32c44586-924f-409c-ad8a-ff459f83bdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3cde5bcd-9046-4493-b593-75cae04e3b97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3cde5bcd-9046-4493-b593-75cae04e3b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_757bdb43-0549-4481-86f0-cbae4616acab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityFileNumber_757bdb43-0549-4481-86f0-cbae4616acab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e96c866c-3dfc-43ad-b82c-a087c26cf12e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityTaxIdentificationNumber_e96c866c-3dfc-43ad-b82c-a087c26cf12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd15ab80-2fa4-4611-903f-e8bc93a10fc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityAddressAddressLine1_fd15ab80-2fa4-4611-903f-e8bc93a10fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_badcc1ae-40ae-402c-bfb8-2dac2eabf113" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityAddressCityOrTown_badcc1ae-40ae-402c-bfb8-2dac2eabf113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1474a8fb-7d58-4e96-87bb-da026f33191c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityAddressStateOrProvince_1474a8fb-7d58-4e96-87bb-da026f33191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ae8975db-e92a-42a7-a4ed-228c4821fe38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityAddressPostalZipCode_ae8975db-e92a-42a7-a4ed-228c4821fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a4a8d6f3-1b74-45d0-bce2-c3189a2464ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_CityAreaCode_a4a8d6f3-1b74-45d0-bce2-c3189a2464ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e3301883-4bb1-4037-972d-a49966d4d7e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_LocalPhoneNumber_e3301883-4bb1-4037-972d-a49966d4d7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1f80f5fa-4e92-4b2e-9edf-04812832e014" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_WrittenCommunications_1f80f5fa-4e92-4b2e-9edf-04812832e014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b09636d1-6d33-41f3-89b7-63bbde51d082" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_SolicitingMaterial_b09636d1-6d33-41f3-89b7-63bbde51d082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_5a4a48b4-7dd8-4549-b5e9-f1613a1d7867" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_PreCommencementTenderOffer_5a4a48b4-7dd8-4549-b5e9-f1613a1d7867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b7d3ff3b-9450-4199-be59-483ef531d9bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b7d3ff3b-9450-4199-be59-483ef531d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_79909715-e91b-46de-8451-d38696d963e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_Security12bTitle_79909715-e91b-46de-8451-d38696d963e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_43409b9f-3916-46f1-8e38-a514f61445c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_TradingSymbol_43409b9f-3916-46f1-8e38-a514f61445c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f1a8c37-487d-417a-8f59-83105c3863d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_SecurityExchangeName_7f1a8c37-487d-417a-8f59-83105c3863d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6f78e2e7-c1ec-4503-b730-8dfe85f6195d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityEmergingGrowthCompany_6f78e2e7-c1ec-4503-b730-8dfe85f6195d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_47b86283-4a2c-4d81-b44d-b5113b9ffef6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_AmendmentFlag_47b86283-4a2c-4d81-b44d-b5113b9ffef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fb63cd74-3fa6-4c12-9ab8-920a09b3d0f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fad1666e-7ab8-4716-ba49-30ae95140bc4" xlink:to="loc_dei_EntityCentralIndexKey_fb63cd74-3fa6-4c12-9ab8-920a09b3d0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20240501_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20240501_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140568894410368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG(%-V!O@^DHI\SZP&];R]X;QOU!+ P04    "  \.*%8GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    "  [.*%8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #LXH5B\(M6-[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( #LXH5B97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .SBA6/L+P$)+!   >Q   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( #PXH5B?H!OPL0(  .(,   -              "  8X,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ /#BA6)>*NQS     $P(   L
M     ( !:@\  %]R96QS+RYR96QS4$L! A0#%     @ /#BA6*K$(A8S 0
M(@(   \              ( !4Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( #PXH5@D'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #PXH5AED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20240501.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nbix-20240501.htm">nbix-20240501.htm</File>
    <File>nbix-20240501.xsd</File>
    <File>nbix-20240501_lab.xml</File>
    <File>nbix-20240501_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20240501_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbix-20240501.htm": {
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20240501",
   "dts": {
    "inline": {
     "local": [
      "nbix-20240501.htm"
     ]
    },
    "schema": {
     "local": [
      "nbix-20240501.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20240501_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20240501_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.neurocrine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20240501.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20240501.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000914475-24-000116-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-24-000116-xbrl.zip
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ME42O3W>/VF,,MD>R0ZHLF[(!88YX0CR)4WU$(T0%1V"M0(/9\48ZIV!.-Z:
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M5*T?R:TV6+51G\*;F>E;(/P!$<[,F(S*@0&( \3R44[*WNQ)\T7/ZP(4;_:
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M\1X1_X$$[Z7T4[_J^\#-_P%02P,$%     @ /#BA6!6/+SQK @  =@<  !$
M  !N8FEX+3(P,C0P-3 Q+GAS9,U5R6[;,!"]^RM8G4MM3F)+B!V@"0(4<!>D
M"9I;05$CFXA$JB05*W]?DA;A*%MCH(?J(G+FO=E'.CWKFQK=@U1,\$60A'&
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M?[420A.)ASQS,&Z!51L/H,SNN'Q7^X2\"?W0&A/*]*&&78G^Y_QK4AR:OZ%
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M/\]YDY"GR<N :X]U]74!5%14@/\H-P!Y!:"J W%W!0 ,#0&2  " #D!M<@U
M15E1_7LP8070_%L#_JW9_O?U/R'/ ;0!EZBH_MW_5Z&^3/U/KM#04%^FO4)+
M^^^@HV>DIZ-CH*.E96!B8&"\2A%:>F86IJO,_];_/N3?V_^]BW*_2D=+=_7_
MLY#; *QT $.J0FJJ6X!+K%34K%3D+@"0HNMEJO\A_U-EJDO4-)>O4%1B8*2<
M4'.-HCXU]26*LI=I**91A5%>!]"P7F:[*:=UA=WD&>TMO^OR;U.^T D]J&SG
M,!U!"RL\]P^G9^#DXN;A%1$5$Y>05%2ZJZQR3U7[H8ZNWB/]QV;F%I96UC:V
M3LXNKFXOW#T"7@6^#H($AT2\BXR*CHF-2TU+S\C,^I"=\[6@L.A;\?>2'[^J
MJFMJZ^H;&CLZN[I[>OOZ!T;'QB<FIZ9G9E=0JVOK&YM;VSN8H^.34^P9[OSB
MGUU4 &JJ_RG_EW:Q4NRZ1(D!#>T_NZ@N!?T[@97F\DVY*VQ:)K3/_-AOR;^E
MN_X@Y4ME.[V0@BF:X[G_" .GL.**".:?:?_#LO]WAH7__[+L?S/L?[=K%G"5
MFHH2/&I6  A )'S]/'ZJ%L9E6-_<7!\U^6=4-"=XPS>E(X[>U57],H!-?YD*
MK %;( -J$T!4FI=F'"$PK\5;F'0[1=/MJ/!;7_*V"@*.2F__U5L,[&N[U7AG
MVB-CYX?Y9-E1U=XF4[K+1, 3SQI)CWV2?I#7C,A$M3;>F0QHUR,HX^6&[D87
MMN6)8E(10ZZI^W5C1_)7#^2UMJ UYS&[U=>,-Y$]H+ECU%D/8W_.68]M7IJ;
MZ/U?(_;;Z%L7K@H;R@3ZH>#R]?G9Q+4I+@4#/[\ (0/%T89@T=?W*'IG"J?J
M[WA\ZF[=(0I=3GGV\Z]M@$$IO-@)!XI7=QP.F'^27_/JQ=)"\971NK.<JK3#
M,-E?NHXU* TGLP;WBL#$YQO/_9TS+VR QS(Y?]&(?2X,<*5ZX((E&>I4M*\N
MK%J] >JY^_Q=**O%E'ZN:4O<Y"Q/A7<%G_/33IY4?;L1\TOZV$LMH>T@]!/C
MQ'RVLDG45+N9^^O#@59$($<\*QE@/WV>GS.28"Z!6*S.^H0T2XM:](DOA=9R
MB(DTA:=Y3O3Z9,]#KY !X8N$1[B 0"9$4O4^J-?V\7N$^J-:U73/L9OIP49A
M<1*@18X+$?P=V$P^"QG@.<RL<181F)%W,*/MZ!XDM;8T[9:\^-#H]85JIO9,
M(LQE-Q^M"T_*K.UY]"J9:;%68;V][+,/(<P<5K,*NXWCP"1CI3!A^;$(12 '
M1,QD='W!JZPMMWRD*5E5?H1#@T&NDSJ<"?I'B#H"0: 7D16[@*?@-[1[/EJD
M%A&K'A1NG08D5+2(3JV(XAV\85@3\&UXNQ(9L/QU$E0;';$V&EA4.TJZ^<(W
M&EF=O!YM$A^)-P<<5Z=2BXEP)WTN 9E,_9XL4#7SS9D _LUV=(_Z[5O9\TQD
MB-[KHGBFXKN4; ],:523'V=)<=Y4C90 4'=T19DKJRY-^HZ=KFI3TW^2R6:V
M&<>'! Z??)P82X\QGM,;_OZ[;9. =5S2)PES!W:XORJC+$X<W/;I,98/HBE+
MN)<9FLTIGA*(?]E4R? 92M2_855I=92U5A8W,%!D_5]"(&)^&'?SC'"=%>D!
M?KO9!A-O/6X.6^9[%3,HY6H(-N)^5*% ,/JH=_-TNI?HXFF:)=FHZ2:*\BF?
MPG)\_;HXN;L 3\%:=2'B8'PXY14;I6%.ST:K:,47SH\*6\:]31=I@M1,#"JI
MA=\##CP3T5;["'0T2B^N[!6(A? $K5E3MF/D5%U9-7DC![4>GGF3U3I3S3Q/
MC=J1F@RXC.:AY(8?)(+4R0LF98C ;"@E)9K.@A,_ZW"D)406D0&C!G$_7IE_
M7NN\BY*L?]*3Q\QJ:)!E%;JS!SN&6A,+U"^C;WER$]Q7@4PX2\.G:K:W2[[K
M>7@_\%HT"^:K/;!?_;9B'T.YQCL"(^C8"B9 B2-VB0R(0[R%+Z_?S.>  LD
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MWJ&UXL#Y!_\8KST7_,OC6MOB<R??V3T6'OZI+Y3D1UI%ADS8FZ>&S$C5A'I
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M<%J>C!,G1<A&DP%>QOS2;U!'GJ%]PV<9^U])GY,[6B.B7_1P%W$AA>!W)\@
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M6(7B<'%*VQB^2FJ'LQ-L*B %^E.4@?Z:^]/I^SGV?NHIC8_M,X\%KMP)90L
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M?$GEE)^,7C3+H9<\]5;%.@2<EI6[F>PZ;$_\OA47_!8*2A:5^/NF7Y*-2GQ
MBP> 5;DQ->ETU,@],&(A/&;@,KMY[$.#B\Q%MUK90J35W1X'Z/^Q^I5_.V6D
M(HX4DJ%Y Y()Y(+@'2?+]TF]7J4>RLHC6LFG$L)E.Q_]VOY304R"(_)H6W&4
M5DRS6S5R*C[+AP?3SBMB5#H?CFH)Y]+M6<'H3CF.Q0AL==B'.#C&1Q_,OS,U
MYIFS&7W87#<BFF@ZV?$T2$<J(>V.2Z>$RE-MIL(*SP,$I0,>Z32#R8#_#):(
MUTY7-V?>B5ER/Y*-+%UJ'23Q$\W:6QF[5NYP5PCWZ(-9C1XSR( "\:/>LZ*S
M!EF0F6*WKP30F.8I C]"!LB!B_+1UH?G2I]H23U2/D2Q>L20AL*A+1G0 CSF
MN+ A RXGD0%I-G_A>\\IB#T:&H<]]CG;DRTEL@RH*U/ 63L&OKL@^^?+^2IZ
M=Z6U'&-FWS#VREISXKO=M+W'):JSS4?LOP.U%K#A]P]T55,<4_",I DSV""(
MI_R49RVE6;;\9?7D%_O\!;>UCRR'#_4UBPR23BEZM4N2 6NGA'_LA&OIXL8D
M@G!]%:M+F;WH,08DMD3.J4%T?KRH^R7=>D--]'IA]%^IHRW0DDE'W$X7JL2\
MJ[FU<=2DD>#=\JI1_6KRS=]W;#@TE0:<S]&G'YV;A#^O2@7&^_OE[.1L!TR
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M:Z-:RZMQ0B^FF,!QMHI(4K\GFDMA,LP97\OZ?QE\DGIB?3M&PT](X:7F%I5
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MYIF#@8%AQKW(:3WLQS2L/>[8Z8?]X]7.QGH[)@^YOP^&CH:2#Q_V!E4LK+;
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M2,$(-L<BKP">U<K;_P#!(K]GBTN8YH_AU:K)"ZR(?[3O>&4@@_Z[U% '%?\
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M-U)5#Z7*I%I_6K9">ZE\-]&/9E*ELRLE[HJT?/SP(&Y8-E>?V5+-N& $0:H
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MSN1[ .,?G>C%B1P[)_O3>138O"M*^/5VY2#-\RQOJ1:$9JB&E)H1K2(EWEG
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M]@-AQ#W,X6(>F(:/=5GXHBFJQ2]8X*3"EG-'C1(J,**"0* 9)C5M7$Z4<"Y
MQ@+5?! *SVWVXV#$/<J!,AX8@NL$+<& A6WW?*Y]M)O>1_1CGN'")K636.<&
M%*3MK[D,#(E,,=P;AURK86O#MVWW@V+$?<H]R3HN."XWFUM(7\[%Y4'$*!PQ
M,J,(NL&Y0&:(U )B)E@P+NX3D6<>] -EQ(W+O4I\Z 4%_"TNBO>,NYNB*6&>
M&T--SC+<##%'I I M,P8"4(KHP(FR8'5Y=<6^^$PXE;E( D/'/Z;9-O_K'V\
M7[FZG$LAJ7$F$F%P\E)%1C3N?8G%V4?%I,P\'13[)^;Z!7[$[<C7BS>2'_W;
MK5_::@'=H_P\,JL][H2DS@,FK=P2'3%I:<%HYA%=$89M*5ZRVH^!$7<=!TLY
MBF[CVQ6D!:+\WU3?-4M<W-:VNI^KF&O@D!//P&/50P5QN:!$AP@Z0Z9-%@81
M\0_&^_UQ:O3]QN'"'IB/<ZQP0EOEO"OM8BYSIQ5O^R:6H^-!,^*D#%@,,R8P
M]T6(PYYG/C'7CX$1MQQ?+]XHLL(%>IYL>8F%[?9GN)]'IX0/N20B6ESA/./$
MM((83BTN?2+0.*P\>-%L/PI&W'T<+N;>:'@S>R;B%9XX.WK\HCVT?XD_._H?
M4$L#!!0    ( #PXH5@8A3*04"\  /37 @ ;    <3$M,C R-'AE87)N:6YG
M<W)E;&5A<V4N:'1M[7UI=]M&LO;W^ROZVKD>.8=$"'"W,CZ'D61'-Y:LD93)
MS/WR'A!HDCT& 0:+).;7OU75  ANXF*1!*&><R:6A*V[EJ>6[J[Z>1 .G8\_
M#[AI?_ROG_^[7&;GGA4-N1LRR^=FR&T6!<+MLS]L'GQCY7)\UYDW&ONB/PB9
M43%J[ _/_R8>3'D]%*'#/R;O^?DG^?O//]%'?NYZ]OCCS[9X8,+^^QM1LXUZ
M4S=J#;W>J_%ZM56I5@W;J/"F;G<K9NW_Z6_@4;A=/A.$8X?__<U0N.4!Q^]_
MJ-=&X>FCL,/!![U2^9\W4_>%_"DLFX[HNQ]HM'"UY[DAC,*'M\H?YUZ^Y*'D
MLN4YGO_A;87^=XI7RCUS*)SQA[_=BR$/V#5_9+?>T'3_5@I,-R@'W!<]>6,@
M_N(P3!@Q_?HHI]"$]SC"Y<F4= /G<?$T$%T1LG9;TZ?'.D\.T^\#1;I>&'K#
M#PUX?68.%C"!^R\^B=I:D[CFD>]9/OR=_2*\P!+<M>#MMWSD^6' /@D_"-D_
M(M.'(4I1^B1<T[6$Z<!-0>3 34L9-3?M%Y^DD4R2WOA!A$!2:XUI7UY_OKWX
MO__K)$-_T5$UM=96PSH=>8$(A0=BS1TS% _\-/1&'\HU#:?YP/U06*832TW7
M##B^X,W'=V_U9NUT)S/9FK[LY,%TNMPU_X)+[V?$Z)J'[,;W[,@*V9WIP#B\
M'ONA7FFP*^$X,'\4/Y\'H!>(;$;U?]B_N>F7OP()RO@3^^Q[C^% R9V2NUFY
MN[NYO;S^[<O%C ">F2/ *OAR9S3RO0>PFMTQ"P><_:[=:>S3>><(9>D,4=OB
M/HT&OW+N1WV<(#QN(CL#UO-\FN4]N@KD-("FG7ENG[OX&=:Q?2"1PWX=C[@_
M<LQ F.PNZ@Y%B(Y%Z!T[B6Y(L!\XNQF V#*#W7NC\A<T=N=F:!)YKG^Y+.N5
M1KU5JY>8R6Z\$&$':$*85;YTRV= %Q"<JYL.2]_7<1PO "P3%KL"( .M\?P2
M$RY0E$SBHP@'[,K\#WS@G+ LP*?.1>#Y-O?7I^1I_!?41[VU2\H^2\>[SC4[
MO[SX_+4$DQHSO42NP(Y5/QY1;;&BE]EBUZ7$+EU+8R?79F";?[Y[6V^=(H__
M]1[$V8:QFZ[K17"CS03PJ9<Z,W[LS"0JTR.3]6=LLKAKPQ-7IF\- /8:E=-J
M3 -XG\T04@3>8+HL&MG@E3,P8OA^NF7RD7XD;/B1:W,2<!@JOGO;,HS*Z1T
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MP+*4V@/@IN>/2TO(P02 %P>V)SZ!M -=#N_A, <'8D0@)[S<Q>?CQ[28,:N
MC6#,V &,K1/LR)C+AIGX1.L/$2BU+WV925#S*]SOX#/! AT-S:[#DU%WB0-E
M&+P#W@7_D/QP"LP!6SK^(%P: CUT.@WM]7G'BD8G+T_"9:TB0^80PN'03KX<
M7];HTD^A/7^M6=.:;6/IY8JF9Z_!R ,0DK^_J;Y)[DOFX'I(GIS<N?;T]8K6
MJ-?7G?X&UZKM[=ZZ<K"MM5[[$\F!OXQL(].V 8X_5)A..K87KK7G/F^,GG
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M!..9(4S3IZ612*0\F"ZM3L7H76#+*&9+0&QYY#Z7[5?BP(!<D;X/P\/6*U1
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MYZ0RE*WG-GA(/OGX<0=Y&45B&W1:\ %Q=#%9!0_YW(5_!^,1]T=P79A*&@X
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M   1              "  0    !N8FEX+3(P,C0P-3 Q+FAT;5!+ 0(4 Q0
M   ( #PXH5@5CR\\:P(  '8'   1              "  =4.  !N8FEX+3(P
M,C0P-3 Q+GAS9%!+ 0(4 Q0    ( #PXH5A8;/FC/D8  -)'   4
M      "  6\1  !N8FEX+3(P,C0P-3 Q7V<Q+FIP9U!+ 0(4 Q0    ( #PX
MH5@!I)#P @H  'U4   5              "  =]7  !N8FEX+3(P,C0P-3 Q
M7VQA8BYX;6Q02P$"% ,4    "  \.*%804&/.JH&  #B,   %0
M    @ $48@  ;F)I>"TR,#(T,#4P,5]P<F4N>&UL4$L! A0#%     @ /#BA
M6!B%,I!0+P  ]-<" !L              ( !\6@  '$Q+3(P,C1X96%R;FEN
C9W-R96QE87-E+FAT;5!+!08     !@ & (\!  !ZF      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>nbix-20240501_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20240501.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
